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Abstract
This is our 8th annual literature review on mechanical circulatory support (MCS)
devices.
Our previous reports were well received by the readers. The full text of the reviews
for 2014, 2015, 2016, 2017, 2018, 2019, and 20201-7 were downloaded 821, 861,
701, 869, 951, 272, and 365 times, respectively.
In this review, we summarized the most interesting and important, from our
standpoint, publications from 2021. There may be some slight overlap with the end
of 2020 because some papers were published online first, and the year of the
publication changed when they became available in print.
For the fifth time, we added a section on extracorporeal membrane oxygenation
(ECMO), which primarily addresses new developments in veno-arterial ECMO.
Readers who wish to supplement this review, argue with the author’s statements, or
express their opinions are encouraged to do so by sending letters to the editor at
mguglin@iu.edu
or
posting
on
our
Facebook
page
at
https://www.facebook.com/TheVADJournal.
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Outcomes
The Society of Thoracic Surgery and the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) 2020 Annual Report reviewed
outcomes in 25,551 patients undergoing primary continuous flow left ventricular
assist device (LVAD) implantation between 2010 and 2019. In 2019, a total of 3,198
primary LVADs were implanted, which is the highest annual volume in the registry
history. The HeartMate 3 (HM3) device (Abbott Laboratories, Abbott Park, IL)
became the dominant choice and accounted for 77% of LVAD implants in 2019.8
There was no difference in 2-year survival (72% versus 74%) between those who
received LVADs from 2014-2016 and those implanted during 2017-2018,
respectively.9 However, this recent analysis also showed that both 1- and 2-year
survival improved when outcomes from 2015-2019 were compared to 2010-2014
(82.3% and 73.1% versus 80.5% and 69.1%, respectively; P < .0001),8 which
indicates overall progress and signals that, as a whole, the field is moving in the
right direction.
There were interesting developments in the outcomes of patients with two
centrifugal devices implanted in the right and left sides (biventricular support). A
systematic literature review of biventricular support was completed by Farag et al.10
Studies that analyzed cases with right atrium (45%) and right ventricle (RV)
cannulation (55%) were included in the review. Thirty-day survival had a median of
90% (interquartile range [IQR] 82–97.8%), and 12-month survival had a median of
58.5% (IQR 47.5–62%). These results are consistent with prior reports.11 According
to data from several centers, when biventricular support used the Heartware
ventricular assist device (HVAD, Medtronic, Minneapolis, MN), survival for 1- and 2years was 56% and 47%, respectively, and there was no difference in survival when
comparing the right atrial and RV implantation techniques of the right-sided device.11
However, per the systematic literature review, a Kaplan-Meier analysis showed a
higher 1-year survival with implantation in the right atrial versus the RV (91.7%
versus 66.2%, P = .036). Pump thrombosis occurred at a similar rate of 30%.12
For the first time, the outcomes of biventricular support with two HM3 pumps were
published in 2021. Previously, a case report referred to this configuration as a
“HeartMate6.”13 In a single-center study from Australia, McGiffin et al. described
their experience with biventricular support (using the HM3 with left ventricle [LV] and
right atrium implantation) in 12 patients.14 The outcomes were dramatically different
from all previous reports. At 18 months after the procedure, 42% (5/12) of cases
received a heart transplant, another 42% (5/12) were alive on biventricular support,
1 (8.3%) patient died, and 1 (8.3%) patient underwent VAD explantation for
myocardial recovery. Actual survival at 18 months was 91.7%.14
In 2021, the HVAD was taken off the market; however, 4,000 patients remain
supported with this device worldwide. In cases of device failure, the only option for
patients who are not transplant candidates is an exchange to the HM3. The
outcomes of such exchanges were collected from the INTERMACS registry.
Although feasible, such exchanges were associated with significantly reduced
survival compared with survival while remaining on HVAD support. At 6 months after
exchange, survival was 73.8% (70% confidence interval [CI], 68.6-77.8%) for an
HVAD to HM3 exchange as compared to 79.0% (70% CI, 78.3-79) for continued
HVAD support. Furthermore, at one year, HVAD to HVAD exchanges had a survival
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of 85.9% (70% CI, 79.5-90.5%) as compared to the 66.6% (70% CI, 63.0-70.0%) (P
= .009) documented after HVAD to HM3 exchanges.15

HeartWare: The End of the Chapter
In the world of mechanical circulatory support (MCS), 2021 will always be
remembered as the year when the HVAD was pulled from the market. The HVAD is
a remarkable device, with an elegantly designed, durable pump. It was the first
intrapericardial LVAD, and it saved or prolonged the lives of thousands of people.
The size and design of this pump allowed for biventricular support. For the first time,
two LVADs could be implanted in the LV and either in the RV or right atrium. Thus,
it is worth reviewing the history of the HVAD and giving credit to notable studies that
advanced the field and taught us many lessons.













A clinical trial demonstrated the noninferiority of Heartware to HMII in terms
of survival on the originally implanted device, transplantation, or explantation
for ventricular recovery at 180 days as well as improvement in functional
capacity and quality of life.16
The FDA approved the device in 2012.
Heartware became the first continuous flow pump used for biventricular
support.17
The Evaluate the HeartWare Ventricular Assist System for Destination
Therapy of Advanced Heart Failure (ENDURANCE) proved a non-inferiority
of HeartWare to HMII in safety and effectiveness. Briefly, survival free from
disabling stroke or need for device replacement at 2 years was 55.0% for
HeartWare and 57.4% for HMII (not significant). The rates of complications
were similar except for stroke which was more prevalent in HeartWare
(29.7% vs. 12.1%, P < .001).18
A post hoc analysis of HeartWare recipients revealed that mean arterial
blood pressure measurements of ≤90 mmHg were associated with a lower
frequency of strokes, particularly hemorrhagic strokes. The ENDURANCE
Supplemental Trial tested the enhanced blood pressure protocol and
showed that it significantly reduced both blood pressure and the incidence
of ischemic stroke.19
The LATERAL trial established that Heartware can be implanted through a
less-invasive approach using a thoracotomy. Over a 6-month follow-up
period, 88% of patients were alive on the original device and free from a
disabling stroke, proving that this approach was a safe and effective
alternative to median sternotomy.20
More than 19,000 devices were implanted over the lifecycle of Heartware.21
The FDA terminated the use of the Heartware device in 2021.

Why did the company and the FDA decide to pull it off the market? Having no access
to inside information, what we can conclude comes from published sources. There
were multiple reasons for the termination of the device’s production.
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Cerebrovascular accidents. The higher rate of cerebrovascular accidents
(CVAs) in patients supported with Heartware as compared to those
supported with HeartMateII (HMII) (Abbott Laboratories, Abbott Park, IL) or
HM3 haunted the device for years after the publication of the ENDURANCE
Page 3 of 22

The VAD Journal: The journal of mechanical assisted circulation and heart failure




study.18 Although there was never a randomized controlled trial, when testing
Heartware against other devices, all comparisons favored other pumps. The
most recent INTERMACS analysis, using propensity score matching,
showed that freedom from stroke of any kind was 82% in Heartware versus
92% in HM3 (P < .001). This difference was bigger in the chronic phase than
in early post-implant.22
Pump thrombosis. The rate of pump thrombosis was reported at 8.1% for
Heartware23 and 1.5% for HM3.24
Recalls. Heartware was the subject of 35 FDA recalls, which was 7-fold that
of HeartMate II. The reasons for recalls included electric discharges leading
to pump failure, malfunctions of the pump controller, and numerous issues
relating to adapter cables and batteries.21,25

It certainly looks like the fully magnetically levitated technology used in the HM3 is
delivering overall better clinical outcomes than hybrid levitation used in the HVAD.
As new data were published, the ability to compete against the HM3 was getting
progressively more difficult. Today, HM3 data has demonstrated superiority in terms
of survival, pump thrombosis, CVA, and gastrointestinal (GI) bleeding. The HM3
pump can support patients with decreased doses of antithrombotics and
anticoagulants, which further diminishes the risk of bleeding complications. All of the
data supports the resulting increasing share of HM3 in new LVAD implants. Yet, the
HVAD remains more suitable for smaller patients, which is a meaningful clinical
advantage. Unfortunately, the number of patients with small torsos is not large
enough to offset all other disadvantages. Kirklin and Stehlik stated, “Medtronic would
have to determine whether improvements to identified shortcomings of the HVAD
would improve clinical outcomes to approximate the results seen with HM3.”26 Thus,
the Medtronic decision to discontinue the pump altogether, except for ongoing
support of already implanted devices, may appear reasonable and responsible from
a business perspective, although it took many physicians by surprise. It is important
to note that prominent figures in the field disagree with the decision. According to O.
Frazier, the decision to abandon HVAD was a “premature and unjustified choice.”21

Candidate Selection
Adult Congenital
Worldwide experience with the use of durable VADs in adult congenital heart
disease is limited, especially when dealing with decompensated systemic RV or a
single ventricle. Several recent publications prompted us to look into this topic.
Although we focus on the adult patients in the present review, some sources
referenced in this section have mixed or even predominantly pediatric cohorts.
As patients with congenital heart disease enter adulthood, their care is often
switched to adult cardiologists; however, the majority of these physicians are not
trained to deal with complex issues such as systemic RV or Fontan circulation. While
adult congenital heart disease specialists take care of such patients, there are
overlapping areas where cardiologists, who were trained in traditional, adultoriented programs, have to make decisions on adult congenital patients. Such areas
include cardiac transplantation and MCS. The experience of durable LVADs
(whether used for RV or LV support) in adult congenital heart disease is limited.
The VAD Journal: Review of 2021
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Because a number of papers on the topic were published in 2021, including a
thorough review by Villa et al.,27 we are briefly reviewing them here.
Single Ventricle (Fontan)
Complications of Fontan circulation include:
 Protein losing enteropathy
 Renal insufficiency
 Sarcopenia
 Plastic bronchitis
 Liver insufficiency
 Hepatocellular carcinoma
Like in traditional cardiomyopathy, the pump is beneficial in VAD patients with
dilated and failing systemic ventricles. In a patient with Fontan circulation, the VAD
is going to be of most benefit when there is systolic dysfunction of a systemic
ventricle with increased end diastolic pressure.
Surgical planning for the VAD implantation in a patient with Fontan circulation is
more complex when compared to adult patients with common ischemic or
nonischemic cardiomyopathy. The VAD implantation in this patient population
commonly results in:
 A decrease in Fontan pressure
 An increase in pulmonary blood flow
 An increase in cardiac output
 Improved oxygen saturation
Given the frequency and severity of liver disease in patients with Fontan circulation,
some advocate for a low threshold for liver biopsy if the noninvasive imaging
provides any concerning results.27 Some centers employ 3-D modeling and virtual
implantations before actual surgery.27 Despite a potential risk of thromboembolism,
placement of fenestrations is also recommended for improved blood oxygenation.27
Existing veno-venous (V-V) collaterals may result in postoperative cyanosis. If the
patient is an adult and has had a Norwood, the ascending aorta is usually quite large
(59 cm), short, and thinned out; therefore, axillary, femoral, or innominate
cannulation should be entertained so placement of a side-biting clamp is possible.27
Other technical challenges to LVAD implantation in patients with Fontan circulation
include:
 Multiple prior sternotomies (can be as many as seven)
 Arterio-venous and V-V collaterals along with liver dysfunction increase the
risk of bleeding
 Arterio-venous collateral flow may require upsizing of bypass cannulas
 If there are concerns about placing the outflow graft on the ascending aorta
(i.e., calcified homograft patch), an outflow graft may be sewn to the
innominate artery
 In RV systemic ventricle, extensive trabeculation excision is required27
Patients with Fontan circulation have one of the highest mortality rates (up to 33%)
on the waiting list for cardiac transplantation.28,29 LVADs are one of very few means
to support them. Last year, the largest study of this patient population (n = 55)
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receiving LVAD support was published on data from INTERMACS and PediMACS.
Only 12 (22%) patients were older than 18 years of age (median age at implantation
was 10.2 years [IQR, 6.4-16.9 years]).30 While 89% of devices were implanted as
systemic VADs (systemic LV support in 66% and systemic RV support in 24% of
patients), the remaining patients received biventricular support or a total artificial
heart. At 6 months, the mortality rate was 76% with 58% of the deaths occurring
during the first month of device support. The median length of support was 3.8
months (IQR, 0.6-6.9 months). Five patients were supported for over one year with
no added mortality; the longest support time was 4 years and 7 months. Adverse
events included pump thrombosis (4%), stroke (5.5%), GI bleeding (7%), and other
bleeding (9%).30 The authors did not provide an analysis of the outcomes based on
the type of support or age of the patients.
Another analysis of patients with Fontan circulation was published from the
Advanced Cardiac Therapies Improving Outcomes Network.31 A total of 45 adult
patients were included in this analysis, and the most commonly employed device
was the HeartWare (56%). A total of 28.9% of patients were discharged on device
support, and 67% of patients experienced adverse events, the most common of
which were neurologic (25%). At 1 year after device implantation, the rate of
transplantation was 69.5%, while 9.2% of patients continued to be VAD-supported,
and 21.3% of patients died. Hemodynamically, VADs were effective in decreasing
both Fontan and ventricular end-diastolic pressures in some individuals. Importantly,
it is unclear how many of these patients overlap with the above-mentioned study
that used the INTERMACS and PediMACS registries.30
Three adult patients (aged 22, 32, and 47 years) received HM3 for systemic
ventricular support at Cincinnati Children’s Hospital. Two patients had Fontan
circulation, and one had transposition of the great arteries, status post Mustard
operation. All three patients survived with a satisfactory quality of life. After the
procedure, both patients with Fontan circulation had a decrease in Fontan and
pulmonary capillary wedge pressure. All three patients experienced an increase in
arterial and mixed venous oxygen saturation. One patient ultimately underwent
heart transplantation 1,104 days after VAD implantation, and the other two patients
remained on HM3 support for 952 and 407 days.32
Another case report described a 22-year-old man with a history of double outlet RV
and mitral atresia. He underwent a Norwood procedure, followed by a bidirectional
Glenn, tricuspid valve annuloplasty, and fenestrated lateral tunnel Fontan with
repeat tricuspid valve annuloplasty by the age of 4. He had mild-to-moderate systolic
dysfunction and tricuspid regurgitation through his teenage years with minimal
functional limitations. He decompensated and required inotropic support with
associated acute kidney and liver injury and new onset atrial tachycardia. He also
later developed aortic insufficiency. He received an HM3 and was successfully
bridged to heart/liver transplantation.33
Systemic RV
Patients with systemic RV typically develop heart failure (HF) in adulthood.
Tadokora et al.34 reported the outcomes of LVAD implantation in four patients. Two
patients underwent congenitally corrected transposition of great arteries and
received EVAHEART (Sun Medical, Nagano, Japan) and HM3 devices. The other
The VAD Journal: Review of 2021
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two patients underwent a Mustard procedure (atrial switch) for transposition of great
arteries and received HMII and HM3 devices. The age of the patients ranged from
34 to 56 years. The median intensive care unit (ICU) stay was 5 days (range 4–17
days), and all patients were discharged from the hospital. One patient was
transplanted four years later, and the others remained on support at the time of
publication. All patients showed increased cardiac output and a substantial
reduction in pulmonary capillary wedge pressure, pulmonary arterial pressure, and
pulmonary vascular resistance. In addition, the severity of tricuspid regurgitation
markedly decreased.

Elderly Patients
In yet another INTERMACS analysis, mortality in patients aged <65 years, 65-75
years, and >75 years was 34%, 54%, and 66%, respectively, with a median followup of 15 months.35 In the most recent years, mortality has decreased with newergeneration devices. When stratified by era, 3-year survival on support significantly
improved in patients >75 years of age. From 2010-2012, survival was 43% for
elderly patients receiving durable LVADs as compared with 46.3% from 2013-2016
and 55.7% from 2017-2020. Interestingly, and paradoxically, complications such as
stroke, device malfunction or thrombosis, and rehospitalizations decreased with
increasing age (all P < .01). Functional status, assessed by a 6-minute walk
distance, and quality of life improved in all age groups.35 Therefore, age over 75
cannot be considered a solo contraindication to LVAD implantation.

Non-inotrope Dependent Patients
Out of the seven profiles of the INTERMACS classification, profiles IV to VII include
patients who do not require inotropic support. The decision to initiate LVAD support
in this group of patients is the most difficult. They are at a relatively low risk of
surgical and early postoperative death; thus, they need to attain a major
improvement in functional status to justify the risk of complications and lifestyle
modifications that come with LVAD implantation. In the past, the Risk Assessment
and Comparative Effectiveness of Left Ventricular Assist Device and Medical
Management in Ambulatory Heart Failure Patients (ROADMAP) study addressed
this group of patients. The ROADMAP was a prospective, multicenter, observational
study. The primary composite endpoint was survival on original therapy with
improvement in 6-minute walk distance. After a two-year follow-up, survival with
improved functional status was better with the HMII LVAD as compared with medical
management alone.36 In 2021, the data from a large French registry studied mortality
in non-inotrope dependent patients receiving an LVAD (303 patients). The overall
likelihood of being alive while on LVAD support or having a transplant at 1, 2, 3, and
5 years was 66%, 61.7%, 58.7%, and 55.1%, respectively. Based on their analysis,
the authors cautioned that such patients might not be the candidates to benefit most
from LVAD implantation.37
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Left Ventricular Size
Two studies, published in 2021, addressed the issue of LV size and outcomes after
LVAD implantation. In the first one, the analysis of the INTERMACS database
(centrifugal devices only) showed that increased LV end-diastolic dimension was
associated with lower mortality (hazard ratio [HR], 0.91; 95% CI 0.84–0.98; P = .01),
stroke (HR, 0.85; 95% CI 0.77–0.93; P < .001), and GI bleeding (HR, 0.88; 95% CI
0.80–0.97; P = .01). Although, there were more arrhythmias in this group (HR, 1.14;
95% CI 1.05–1.24; P = .003). The patients in the lowest quartile with an LV size <6.1
cm had the worst survival rate.38
In another cohort of 313 patients with a centrifugal-flow LVAD from the Medstar
Washington Hospital Center, a cut-off point of 59 mm for LV end-diastolic diameter
predicted worse survival. In patients with smaller ventricles, survival was lower than
in larger LV end-diastolic diameter patients (71% versus 85% at 1 year; 58% versus
80% at 2 years, P = .003). The incidence of late RV failure (23% versus 12%, P =
.02) and need for temporary RV mechanical support was significantly higher in the
smaller LV cohort (11.5% versus 1.9%, P = .002). Pump flows at the time of
discharge were lower in the smaller LV group (3.8 versus 4.2 L/min, P = .005). The
smaller LV group also had a higher rate of GI bleeding (0.416 versus 0.256 events
per patient-year, P = .025), and higher readmissions secondary to low flow alarms
(0.429 versus 0.240 events per patient-year, P = .007).39

Management of Patients on LVAD Support
Aortic Changes
Chronic LVAD support changes cardiovascular physiology and results in structural
changes. Investigators reported a significant increase in the thickness of the
collagen-rich adventitial layer in the aorta, and the amount of fibrosis correlates with
the duration of LVAD support.40 The aortic wall becomes stiffer on LVAD support,
especially if the device is run at a high speed. Patients with increased aortic stiffness
have a higher rate of a composite outcome of GI bleeding, stroke, and pump
thrombosis.41

Pregnancy on LVAD
A review included all publications on LVAD-supported pregnancies and described 6
women from 19 to 36 years of age. All cases suffered from nonischemic
cardiomyopathy and conceived while on LVAD support. One pregnancy ended with
fetal demise, but the other five women delivered, mainly via cesarean section.42
Another case report, not included in the above review, described a successful
pregnancy of a 23-year-old woman on LVAD support who delivered a healthy baby
via cesarean section. Of note, the LVAD speed was increased in the last trimester.43

Medical Management
In our prior annual reviews, we summarized papers reporting beneficial effects of
the continuation of guideline-directed medical therapy. Last year, another study
highlighted the difference between angiotensin-converting enzyme inhibitors
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(ACEI/ARB) and mineralocorticoid receptor antagonists.44 Per the analysis of the
International Society for Heart and Lung Transplantation Registry for Mechanically
Assisted Circulatory Support (ISHLT IMACS), the Kaplan-Meier survival was
significantly better for patients receiving ACEI/ARB (P < .001) but not aldosterone
antagonists. A Cox proportional hazard analysis was adjusted for known predictors
of mortality following LVAD implantation, and ACEI/ARB (HR 0.81 [95% CI 0.710.93], P < .0001) but not aldosterone antagonists (HR 1.03 [95% CI 0.88-1.21], P =
.69) were independently associated with lower mortality. Among patients treated
with ACEI/ARB, there was a significantly lower unadjusted risk of cardiovascular
death (P < .001), GI bleeding (P = .01), and a lower creatinine level (P < .001).
Aldosterone antagonist therapy was associated with a lower risk of GI bleeding (P
= .01), but a higher risk of hemolysis (P < .01).44
With the ongoing enthusiasm for sacubitril/valsartan in the HF community, the
experience of using this drug in the LVAD population is also growing. After the first
series of 5 patients was published in 2020,45 more reports were published in 2021.
The use of angiotensin receptor-neprilysin inhibitors (ARNIs) was reported in a 10patient cohort from the Cleveland Clinic,46 and another report included 22 patients
from several European countries.47
One study analyzed 21 patients on stable LVAD support who were initiated on
sacubitril/valsartan. While 5 patients could not tolerate the drug, 16 (76%)
successfully initiated sacubitril/valsartan therapy and were assessed at baseline and
3 months. Sacubitril-valsartan was kept at 24/26 mg (twice a day) in 37% of patients,
uptitrated to 49/51 mg (twice a day) in 44% of patients, and reached 97/103 mg
(twice a day) in 19% of patients. The mean arterial pressure trended lower at 3
months (89 ± 8 to 83 ± 10 mmHg, P = .09). Daily loop diuretic requirements also
decreased significantly as furosemide equivalents fell from 143 ± 145 to 79 ± 94
mg/day (P = .007), and functional capacity improved.48
In a study out of Columbia, 30 patients tolerated ARNi for at least 3 months. The
NT-proBNP levels significantly decreased from a median of 1265 pg/mL at initiation
to 750 pg/mL at 3 months and 764 pg/mL at 6 months (P = .01). There was a trend
toward a decrease in blood pressure, with a median mean arterial pressure of 91.5
mmHg at initiation, 88.5 mmHg at 3 months, and 83.0 mmHg at 6 months (P = .14).49

Kidneys
The renal function typically improves after LVAD implantation; improvement is very
steep in the first month and then incurs a subsequent and gradual decline.50 Patients
with severely compromised function before the LVAD implantation experience a
greater improvement. By the end of the first six months of support, the estimated
glomerular filtration rate is usually greater than before the surgery.50 Last year, a
detailed study on renal function post-LVAD implantation described changes over 8
years of support.51 Although a gradual decline in function continues, at the end of
the study, the glomerular filtration rate was still very good (50 to 60 mL/min/1.73m2).
Patients with a preoperative estimated glomerular filtration rate less than 50
mL/min/1.73m2 benefited the most. The post-LVAD implantation survival did not
differ between patients with pre-LVAD glomerular filtration rates above and below
60 mL/min/1.73 m2.51
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Nevertheless, individual programs often hesitate to implant an LVAD in patients with
severely compromised kidney function. While end-stage renal disease requiring
continuous renal replacement therapy (CRRT) is a contraindication to LVAD per
ISHLT guidelines,52 there is no guidance on potential kidney failure after the
implantation. Although the transition to end-stage renal disease after LVAD
implantation is infrequent, it does occur, and long-term care for dialysis-dependent
patients on LVAD support is challenging. We previously reported our experience
with such cases.53 The barriers to finding a hemodialysis center for an LVADsupported patient include:
 No detectable blood pressure in a large proportion of patients, which requires
the need for Doppler to monitor blood pressure
 Chronic anticoagulation resulting in increased bleeding risk
 Increased infection risk with regular intravenous access, especially in the
presence of dialysis catheters
 Significant hemodynamic shifts due to rapid removal of large amounts of
fluid, triggering symptoms of dehydration and suction events
 Unfamiliarity with technology among dialysis personnel and presumption of
LVAD patients as “high risk”
There are also concerns about proper maturation of an arteriovenous fistula in the
setting of decreased vascular reactivity, although some studies reported normal
maturation.54 Importantly, peritoneal dialysis offers advantages and disadvantages.
Advantages:
 Lower risk of infectious complications
 Opportunity to perform dialysis at home
 Sustained daily ultrafiltration with peritoneal
hemodynamic stability
 Better preservation of residual renal functions
 Higher chance of renal recovery

dialysis

offers

more

Disadvantages:
 Danger of the driveline going through the peritoneal space
 Lack of precision/predictability on the amount of fluid removal
 Potential worsening of diabetes mellitus due to the continuous glucose
absorption from glucose containing peritoneal dialysis solutions
 Nutritional risk due to peritoneal albumin losses
There are very few cases published on peritoneal dialysis in patients with LVADs.
Two of them were published in 2021, but because there are so few, all will be listed
in this review.
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A 63-year-old man required peritoneal dialysis before LVAD implantation. As
kidney function improved, he was taken off dialysis. In the postoperative
period, peritoneal dialysis was again required for 11 days, after which he
suffered a stroke and was transitioned to comfort care.55
A 78-year-old man had cholesterol embolic disease and started on
hemodialysis while on LVAD support. Unfortunately, he could not tolerate
the hemodialysis because of hypotension and suction events. The lines had
to be removed due to bacteremia. Because the LVAD driveline exited in the
left lower quadrant of the patient’s abdomen, the peritoneal dialysis catheter
was placed in the right lower quadrant as far from the driveline as feasible.
Page 10 of 22
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A year later, he was comfortable on home peritoneal dialysis, with no
episodes of peritonitis and no hospitalizations for HF.56
A 55-year-old patient developed end-stage renal disease 6 years after
receiving an HVAD; peritoneal dialysis was initiated. The LVAD flow was
steady. The patient died from encephalitis 16 months later.57
A woman in her 50’s developed end-stage renal disease after LVAD
implantation and could not tolerate outpatient hemodialysis due to
hypotension. She was transitioned to peritoneal dialysis and tolerated it well
for 6 weeks. Her kidney function then recovered, and she was taken off
dialysis.58

It is noteworthy that in no instance did these patients develop complications of
peritoneal dialysis, providing support that this therapy might be a valuable option to
explore in patients who develop end stage renal disease after the LVAD
implantation.

Pulmonary Hypertension
Pulmonary hypertension in HF is well studied. It is known that compensation of HF
with normalization of filling pressure alleviates pulmonary hypertension, but rarely
normalizes pulmonary arterial pressure. Reactive pulmonary hypertension is of
particular clinical importance because it persists after normalization of intracardiac
pressures. The INTERMACS analysis provided interesting data on the effects of
LVAD on pulmonary hypertension in patients with pulmonary vascular resistance
greater than 3 Wood units before LVAD implantation.59 It appeared that in these
patients, pulmonary vascular resistance decreased by 1.53 Wood units (95% CI
1.27-1.79) per month in the first 3 postoperative months and by 0.066 Wood units
(95% CI 0.060-0.070) per month thereafter. Severe mitral regurgitation at any time
during follow-up was associated with 1.29 Wood units (95% CI 1.05-1.52) higher
pulmonary vascular resistance relative to absence of mitral regurgitation at that time.
Importantly, 15%-25% of patients had persistently elevated pulmonary vascular
resistance of greater than 3 Wood units at any given time within 36 months after
LVAD implantation.59

Arrhythmia and Electrophysiology
Cardiac Resynchronization Therapy
Multiple publications have reported that cardiac resynchronization therapy (CRT)
does not affect outcomes in patients with LVADs. Intuitively, because the circulation
in these patients is provided by both the continuous flow pump and the patient’s own
LV, biventricular pacing should still be of some benefit. Indeed, Tomashitis et al.
studied patients with LVADs who underwent right heart catheterizations that were
performed at different pacemaker configurations (biventricular pacing, left
ventricular pacing, RV pacing, and no pacing) in a randomly generated sequence
for >3 minutes between configurations. RV contractility, as assessed by RV maximal
change in pressure over time normalized to instantaneous pressure, was higher in
biventricular pacing as compared with unpaced conduction (15.7 ± 7.6 versus 11.0
± 4.0 s-1, respectively; P = .003). Cardiac output was higher in biventricular pacing
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when compared with unpaced conduction (4.48 ± 0.7 versus 4.38 ± 0.8 L/min,
respectively; P = .05). There were no significant differences in heart rate, ventricular
filling pressures, or atrioventricular valvular regurgitation across all pacing
configurations.60 The data from the multinational Trans-Atlantic Registry on VAD and
Transplant also showed no differences in survival when comparing the presence or
absence of CRT. Interestingly, in comparison to no device, only CRT with a
defibrillator was associated with late RV failure (HR 2.85, 95% CI 1.42-5.72, P
= .003). There was no difference in risk of early RV failure across the groups or risk
of implantable cardioverter defibrillator (ICD) shocks between those with ICD and
CRT-defibrillator.61
This topic received an unexpected development in the prospective randomized
crossover study of Chung et al.62 LVAD patients with prior CRT devices were
alternated on RV and biventricular pacing for planned 7-14-day periods. Compared
with biventricular pacing, RV-only pacing resulted in a 29% higher mean daily step
count, 11% greater 6-minute walk test distance, and 7% improved quality of life
score (all P < .03). LV end-diastolic volume was significantly lower with RV pacing
(220 versus 250 mL; P = .03). Fewer patients had ventricular tachyarrhythmia
episodes during RV pacing (P = .03). RV lead impedance was lower with RV pacing
(P = .047), but no significant differences were observed in impedance across other
CRT leads. This study supports turning off LV lead pacing in LVAD patients with
CRT. To explain this finding, the authors hypothesized that biventricular pacing may
induce contraction, which places the septum or free wall closer to the LVAD inflow
cannula, increasing the risk of suction events.

Ventricular Tachycardia
Ventricular tachycardia remains a problem in patients with LVADs, and it continues
to contribute to mortality rates. In the cohort from Duke University, electrical storm,
defined as at least 3 sustained episodes of ventricular tachycardia over a 24-hour
period without an identifiable reversible cause, was experienced by 10.7% of
patients at a median time of 269 (IQR 7-766) days following surgery. Following
electrical storm, 41% of patients died within 1 year.63
Ablation may be a very effective method to treat ventricular tachycardia in LVADsupported patients. In patients with an HM3, ablation was mostly successful. Noninducibility was reached in 58% of patients, although 26% required a redo ablation
during the follow-up.64
Cardiac sympathetic denervation may be an alternative or supplemental approach
to reduce ventricular tachycardia and has been shown to reduce sustained
ventricular arrhythmias and ICD shocks by inhibiting sympathetic outflow to the
heart. Last year, the success of this strategy was described for the first time in a
patient on LVAD support.65

Complications of LVADs
Driveline Injury
Driveline damage is rarely discussed in the literature, but last year it received some
attention. D’Antonio et al.66 analyzed 55 cases from the published literature on
driveline damage. Almost all patients (53/55) were supported by HMII devices.
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Internal damage was more commonly reported than external damage (69.1% versus
30.9%, respectively, P = .01). Median time to driveline damage was 1.9 years (IQR
1.0, 2.5). Most patients (94.5%) presented with an LVAD alarm, and patients with
internal driveline damage had a significantly higher rate of alarm activation as
compared to those with external damage (100% versus 82.4%, respectively, P
= .04). In terms of management, 14.5% of patients underwent external repair of the
driveline, 5.5% were treated with rescue tape, and 5.5% were placed on an
ungrounded cable indicating a short-to-shield event had occurred. A total of 49.1%
of patients underwent pump exchange, 5.5% were explanted, and 5.5% underwent
emergent heart transplantation. The 30-day mortality rate was 14.5%.66
Not included in D’Antonio’s67 analysis was our cohort of 13 patients with driveline
fracture (11.8% of our total LVAD single-center population at that time). We found
that the mean time from implant to fracture was 23 ± 16.5 months, and the majority
(62%) of fractures were external due to trauma (i.e., cut during dressing change).
Usually due to unknown causes, internal injury proximal to the cutaneous exit site
occurred in 38% of patients. Only 1 (7.6%) patient survived on continued LVAD
support. One individual survived and underwent LVAD explantation, 2 underwent
pump exchange, and 4 others underwent heart transplantation. The remaining 5
patients expired. All patients (60%) with untreated internal fractures died.67

Gastrointestinal Bleeding
It is widely accepted that GI bleeding in patients supported with LVADs occurs due
to angiodysplasias in the small bowel that develop at an accelerated rate due to a
non-pulsatile flow and bleed easily because of acquired von Willebrand factor
deficiency and chronic anticoagulation. In 2021, Patel et al.68 published a paper that
challenges this concept. The authors compared the number of angiodysplasias
revealed by capsule endoscopy in patients with and without HF. The prevalence of
angiodysplasias was significantly higher in the HF with reduced ejection fraction
group as compared to the non-HF controls (50% versus 13%, respectively, P =
.0002). This association persisted after controlling for age and comorbidities. Within
the HF cohort, higher angiotensin 2, NT-proBNP, and blood urea nitrogen levels
were associated with the presence of angiodysplasias. Moreover, patients with
severe HF (by New York Heart Association class) was associated with more
angiodysplasias. Out of a total of 25 angiodysplasias, 23 were located in the small
gut.68 If indeed congestion produces angiodysplasia, it explains why optimization of
hemodynamics results in reduction of GI bleeding.69
Another study showed that RV enlargement and tricuspid regurgitation before LVAD
implantation were predictive of GI bleeding after the implantation. Also, the rate of
GI bleeding in patients with LVADs without RV failure was 14.8%. In patients with
mild and moderate RV failure, the rate increased to 24.2% and 23.6%, respectively
(P < .0001).70 This association of GI bleeding with RV failure may also explain
another report that endoscopic evaluations and interventions for GI bleeding in
patients with LVADs do not reduce further bleeding events,71,72 but the use of digoxin
does.73 Although, Jennings et al.74 reviewed INTERMACS data and reported that
use of ACEi/ARB, aldosterone antagonists, amiodarone, and digoxin did not appear
to be associated with GI bleeding during LVAD support.
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Different VADs and Devices
Intra-aortic Balloon Pumps
With the new listing rules for cardiac transplantation, the use of short-term MCS
devices has increased. Almost inevitably, they keep patients bedridden, which
compromises their functional status. Hence, there is a growing interest in devices
that allow some mobility. Intra-aortic balloon pumps (IABPs) are the easiest to place
and the most used MCS devices. Axillary placement of an IABP allows patients to
walk; however, the rate of complications is quite high.
In the last year’s review,7 we cited the Houston Methodist experience of 195 axillary
IABPs in which 37% of patients needed replacement due to malfunction.75 This year,
investigators from the University of Chicago reported their data on 241 patients with
an IABP. The devices were inserted through a graft sutured onto the axillary artery
in 142 (58.9%) patients and percutaneously in 99 (41.1%) patients. The IABP was
placed from the right axillary artery in 147 (61.0%) patients and left in 94 (39.0%)
patients. Ambulation was possible in 90% of patients during support with this device.
In total, 5.4% of patients died, and 4.1% required escalation of mechanical support.
IABP-related stroke occurred in 6 (2.5%) patients. In 27.8% of cases, the pump had
to be replaced due to various complications.76 It appears that even in the best
centers, the rate of complications remains high.
In the management of cardiogenic shock, in-hospital mortality was lower with the
use of the IABP than without (27% versus 43%, adjusted OR 0.53, 95% CI 0.40–
0.72, P < .0001). Use of the IABP was associated with lower crude in-hospital
mortality in each of the Society for Cardiovascular Angiography & Intervention’s
shock stages (all P < .05, except P = .08 in shock stage E).77 Moreover, it appears
that in some patients, the hemodynamic benefit of the IABP may be substantially
greater than the conventional estimate of 0.5 L/min increment in cardiac output. In
fact, responders to IABPs demonstrated an increase of 1.21 ± 0.87 L/min. Systemic
vascular resistance >1300 dynes/sec/cm−5 (OR, 5.04; 95% CI, 1.86-13.6; P < .01)
and moderate-severe mitral regurgitation (OR, 2.42; 95% CI, 1.25-4.66; P < .001)
predicted robust hemodynamic response.78

What is new in the V-A ECMO World?
The utilization of V-A ECMO for the management of cardiogenic shock continues to
grow. There is more evidence in favor of early initiation of ECMO in shock. In a
multicenter registry, participants were classified into 3 groups according to terciles
of shock-to-ECMO time (early, intermediate, HR: 0.53; 95% CI: 0.28 to 0.99). Early
ECMO support was also associated with lower risk for the following:
 in-hospital mortality,
 ECMO weaning failure,
 composite of all-cause mortality and rehospitalization for HF at 1 year,
 all-cause mortality at 1 year, and
 poor neurological outcome at discharge.79
In terms of outcomes of cardiogenic shock by etiology, a meta-analysis of patients
receiving V-A ECMO support showed a mortality of 35% (95% CI: 29−42) in posttransplant patients, 40% (95% CI: 33−46) for myocarditis, 53% (95% CI: 46−59) for
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HF, 52% (95% CI: 38−66) for pulmonary embolism, 59% (95% CI: 56−63) for
cardiotomy, 60% (95% CI: 57−64) for acute myocardial infarction, 64% (95% CI:
59−69) for in-hospital cardiac arrest, and 76% (95% CI: 69−82) for out-of-hospital
cardiac arrest (P < .001).80 Another study on post-cardiotomy cardiogenic shock
reported a very similar mortality rate of 58.3%.81
In past reviews, we discussed the principles and benefits of LV unloading during VA ECMO support. A recent study highlighted the benefits of an overall negative fluid
balance in such patients.82 If patients receiving ECMO support and CRRT can
achieve a negative fluid balance, they have an improved survival rate. After 72
hours, the treatment group had a fluid balance of -3840 mL versus +425 mL in
patients on ECMO but not CRRT (P ≤ .05). This lower fluid balance correlated with
survival to discharge (OR 2.54, 95% CI 1.10-5.87). Improvement in the ratio of
arterial oxygen content to fraction of inspired oxygen was also significantly higher in
the CRRT group as compared to the renal dysfunction group (102.4 versus 0.7,
respectively, P ≤ .05).82
Additional data were published on the combination of V-A ECMO and Impella
(Abiomed, Danvers, MA) support for patients with cardiogenic shock. LV unloading
was studied in a propensity matched cohort of patients from 16 institutions. LV
unloading was associated with a lower 30-day mortality (HR, 0.79, 95% CI, 0.63–
0.98; P = .03). Complications, not surprisingly, were seen more frequently in patients
with a combination of ECMO/Impella support.83
In a retrospective, single-center study, patients supported by V-A ECMO alone were
compared to patients supported with a combination of ECMO/IABP and
ECMO/Impella. ECMO/Impella patients had a higher incidence of bleeding events
compared with ECMO alone or ECMO/IABP (52.8% versus 37.1% versus 17.7%,
respectively; P < .0001). Compared with ECMO alone, ECMO/IABP provided better
survival at 180 days (P = .005), whereas survival in ECMO/Impella was not different
from ECMO alone.84
As the experience with V-A ECMO is growing, it is utilized in more clinical scenarios.
Thus, V-A ECMO for support of thyrotoxicosis-induced cardiomyopathy complicated
by cardiogenic shock was reported by several authors.85,86 At our institution, a
patient with a LVEF of 10% due to thyrotoxicosis-related cardiomyopathy underwent
an emergency thyroidectomy while on V-A ECMO support which resulted in almost
immediate recovery of myocardial function.85 Another group of authors reported a
case where the ECMO circuit was used for therapeutic plasmapheresis for T4
removal, which resulted in a significant improvement in thyroid and cardiac function.
In their case, a total thyroidectomy was performed two weeks later.86
Another interesting clinical scenario was reported in several publications last year.
Although rare, cardiac tamponade may occur in about 2% of patients supported by
ECMO.87 For a number of reasons, the diagnosis can be challenging. Physical
diagnosis of tamponade based on the presence of pulsus paradoxus is unfeasible
in a patient supported with continuous flow V-A ECMO. Hypotension with narrow
pulse pressure and neck vein distension are unreliable in this situation as well.
Pericardial effusion can certainly be seen on echocardiography, but ventricular
interdependence may not be present because the circulation is mostly provided by
a continuous flow device. It appears that any chamber collapse may be an indication
for an emergency drainage of the pericardium.88 The diagnosis may be even more
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challenging in a patient on a combination of V-A ECMO and Impella support, as both
provide a continuous flow circulation. In our case, a newly discovered moderate
pericardial infusion and increasing pressure requirements justified the pericardial
drainage with an immediate improvement of hemodynamics.89
V-A ECMO is also used to support patients in electrical storm to maintain
hemodynamics until they are treated for electrical instability. In a single-center study,
patients supported by ECMO for this indication had a survival rate of 64.7%.90
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